SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-034168
Filing Date
2024-03-20
Accepted
2024-03-20 16:10:31
Documents
13
Period of Report
2024-03-20
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fusn-20240320.htm   iXBRL 8-K 42726
2 EX-99.1 fusn-ex99_1.htm EX-99.1 153763
3 GRAPHIC img92740539_0.jpg GRAPHIC 2668
  Complete submission text file 0000950170-24-034168.txt   339207

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT fusn-20240320.xsd EX-101.SCH 32041
16 EXTRACTED XBRL INSTANCE DOCUMENT fusn-20240320_htm.xml XML 4875
Mailing Address 270 LONGWOOD ROAD SOUTH HAMILTON A6 L8P 0A6
Business Address 270 LONGWOOD ROAD SOUTH HAMILTON A6 L8P 0A6 289-799-0891
Fusion Pharmaceuticals Inc. (Filer) CIK: 0001805890 (see all company filings)

IRS No.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39344 | Film No.: 24767878
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)